Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials
- PMID: 26051432
- DOI: 10.1016/j.medcli.2015.03.014
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials
Abstract
Background and objective: Romiplostim and eltrombopag are thrombopoietin receptor (TPOr) agonists that promote megakaryocyte differentiation, proliferation and platelet production. In 2012, a systematic review and meta-analysis reported a non-statistically significant increased risk of thromboembolic events for these drugs, but analyses were limited by lack of statistical power. Our objective was to update the 2012 meta-analysis examining whether TPOr agonists affect thromboembolism occurrence in adult thrombocytopenic patients.
Materials and methods: We conducted a systematic review and meta-analysis of randomized controlled trials (RCTs). Updated searches were conduced on PubMed, Cochrane Central, and publicly available registries (up to December 2014). RCTs using romiplostim or eltrombopag in at least one group were included. Relative risks (RR), absolute risk ratios (ARR) and number needed to harm (NNH) were estimated. Heterogeneity was analyzed using Cochran's Q test and I(2) statistic.
Results: Fifteen studies with 3026 adult thrombocytopenic patients were included. Estimated frequency of thromboembolism was 3.69% (95% CI: 2.95-4.61%) for TPOr agonists and 1.46% (95% CI: 0.89-2.40%) for controls. TPOr agonists were associated with a RR of thromboembolism of 1.81 (95% CI: 1.04-3.14) and an ARR of 2.10% (95% CI: 0.03-3.90%) meaning a NNH of 48. Overall, we did not find evidence of statistical heterogeneity (p=0.43; I(2)=1.60%).
Conclusions: Our updated meta-analysis suggested that TPOr agonists are associated with a higher risk of thromboemboembolic events compared with controls, and supports the current recommendations included in the European product information on this respect.
Keywords: Eltrombopag; Ensayo clínico aleatorizado controlado; Meta-analysis; Randomized controlled trials; Romiplostim; Thrombocytopenia; Thromboembolism; Thrombosis; Trombocitopenia; Tromboembolismo; Trombopoyetina; Trombosis.
Copyright © 2015 Elsevier España, S.L.U. All rights reserved.
Similar articles
-
Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials.Med Clin (Barc). 2012 Oct 20;139(10):421-9. doi: 10.1016/j.medcli.2011.11.023. Epub 2012 Jan 23. Med Clin (Barc). 2012. PMID: 22266082 Review.
-
Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.Expert Opin Pharmacother. 2017 Oct;18(15):1543-1551. doi: 10.1080/14656566.2017.1373091. Epub 2017 Sep 4. Expert Opin Pharmacother. 2017. PMID: 28845713 Review.
-
Eltrombopag versus romiplostim in treatment of children with persistent or chronic immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis.Sci Rep. 2018 Jan 12;8(1):576. doi: 10.1038/s41598-017-19099-8. Sci Rep. 2018. PMID: 29330464 Free PMC article. Review.
-
Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: A systematic review incorporating an indirect-comparison meta-analysis.PLoS One. 2018 Jun 1;13(6):e0198504. doi: 10.1371/journal.pone.0198504. eCollection 2018. PLoS One. 2018. PMID: 29856837 Free PMC article.
-
Thrombopoietin mimetics for patients with myelodysplastic syndromes.Cochrane Database Syst Rev. 2017 Sep 30;9(9):CD009883. doi: 10.1002/14651858.CD009883.pub2. Cochrane Database Syst Rev. 2017. PMID: 28962071 Free PMC article. Review.
Cited by
-
Aplastic Anemia With Thrombosis Following the Administration of Immunosuppressant and Thrombopoietin Receptor Agonist (TPO-RA).Cureus. 2024 May 26;16(5):e61135. doi: 10.7759/cureus.61135. eCollection 2024 May. Cureus. 2024. PMID: 38800784 Free PMC article.
-
Primary Immune Thrombocytopenic Purpura (ITP) and ITP Associated with Systemic Lupus Erythematosus: A Review of Clinical Characteristics and Treatment Modalities.Int J Rheumatol. 2024 Mar 1;2024:6650921. doi: 10.1155/2024/6650921. eCollection 2024. Int J Rheumatol. 2024. PMID: 38464849 Free PMC article. Review.
-
Thrombopoietin receptor agonists use and risk of thrombotic events in patients with immune thrombocytopenic purpura: A systematic review and meta‑analysis of randomized controlled trials.Biomed Rep. 2024 Jan 22;20(3):44. doi: 10.3892/br.2024.1732. eCollection 2024 Mar. Biomed Rep. 2024. PMID: 38357229 Free PMC article.
-
Hyperlipidemia in immune thrombocytopenia: a retrospective study.Thromb J. 2023 Oct 2;21(1):102. doi: 10.1186/s12959-023-00545-9. Thromb J. 2023. PMID: 37784127 Free PMC article.
-
Immune thrombocytopenia and cerebral thrombophlebitis in a patient on eltrombopag: A rare complication.Radiol Case Rep. 2023 Apr 5;18(6):2069-2072. doi: 10.1016/j.radcr.2023.03.006. eCollection 2023 Jun. Radiol Case Rep. 2023. PMID: 37064078 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources